News

Achillion is involved in the development of oral small molecule Factor D inhibitors for the treatment of people with complement alternative pathway-mediated rare diseases such as paroxysmal nocturnal

The agreement allows CRISPR, a Swiss gene editing company, to gain access to the KSQ Therapeutics’ intellectual property (IP) for editing certain gene targets in its allogeneic oncology

“This partnership will significantly widen Trialbee’s service offerings to drive patient recruitment and retention,” said Lollo Eriksson, CEO of Trialbee. “This is a great opportunity to leverage both

Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor (SNRI) designed for the treatment of various neuro-psychiatric and pain disorders in patients who have difficulty swallowing – a

The divestment is part of Takeda’s strategy to focus on core business areas and facilitate rapid deleveraging following its acquisition of Shire. Takeda growth and emerging markets business

According to the life sciences company, the technology used by the IonicX XRF Analyzer helps save time and money that is otherwise used on conventional analysis techniques. This

Over time, patients taking levodopa may begin to experience periods when PD symptoms, including motor fluctuations, re-emerge between treatment doses. These are called “off” episodes. “We are pleased

Simultaneously, the company completed a Series C financing led by HBM Partners with participation from new and existing investors. AVID200 is rationally designed to selectively and potently inhibit

The approval has been granted for Xarelto to prevent venous thromboembolism (VTE) or blood clots in hospitalised acutely ill medical patients at risk for thromboembolic complications who are